Transcriptomics

Dataset Information

0

Potential Roles of miR-29a in the Molecular Pathophysiology of T-Cell Acute Lymphoblastic Leukemia


ABSTRACT: The miR-29 family is an important player in the molecular pathophysiology of distinct types of cancer, with roles that seems to depend on cellular context. Reduced miR-29 levels are associated with more aggressive disease and its overexpression in cancer and leukemic cell lines inhibits proliferation. In contrast, its overexpression in hematopoietic progenitors, promotes leukemogenesis. We explored the potential roles of miR-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia (T-ALL). As compared to normal T-cells, miR-29a levels are extremely reduced in T-ALL and in the Jurkat cell line. Microarrays analysis in Jurkat cells, following the introduction of synthetic miR-29a mimics, revealed the down-regulation of several predicted targets, including previously described targets (DNMT3a/b, CDK6, PXDN, MCL1, PIK3R1 and CXXC6), and novel targets with roles in active DNA demethylation, such as members of the ten-eleven-translocation (TET) family and TDG. Reduced miR-29a levels contribute to altered epigenetics, as its introduction in Jurkat cells, promotes the demethylation of the AHR gene (commonly methylated in T-ALL). In T-ALL patients, miR-29a levels are significantly associated with blast counts and disease free survival. Our results highlight the relevance of miR-29 in T-ALL physiopathology, and may help to clarify some contrasting findings reported in the literature.

ORGANISM(S): Homo sapiens

PROVIDER: GSE48063 | GEO | 2013/09/01

SECONDARY ACCESSION(S): PRJNA208843

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-09-01 | E-GEOD-48063 | biostudies-arrayexpress
2016-10-05 | GSE87609 | GEO
2019-01-23 | GSE65704 | GEO
2020-11-04 | PXD016430 | Pride
2020-11-04 | PXD016358 | Pride
2023-05-16 | GSE218946 | GEO
2014-01-17 | E-GEOD-53143 | biostudies-arrayexpress
2024-06-13 | PXD037998 | Pride
2024-06-13 | PXD037862 | Pride
| PRJNA208843 | ENA